Long-Term Indications from INDIGO Trial: VORANIGO®'s Impact on IDH-Mutant Glioma
On November 17, 2026, Servier presented compelling findings at the Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia concerning the efficacy of VORANIGO® (vorasidenib) in treating patients with IDH-mutant gliomas. These results stem from an extensive follow-up of the Phase 3 INDIGO trial, providing critical insights into the medication's enduring clinical benefits across various patient subgroups.
Highlights of the Study Findings
The presentation emphasized results from patients who transitioned from placebo to VORANIGO, giving an overview of the clinical benefits observed over a median follow-up of 41.6 months. This substantial time frame underscored the sustained improvement in progression-free survival (PFS) among patients treated with VORANIGO post-surgery, particularly those with Grade 2 gliomas, a condition severely impacting quality of life.
Key Results:
- - Crossover Insights: Among the 144 patients initially randomized to placebo, significant results were noted after they crossed over to VORANIGO. The median PFS was reported at 37.2 months.
- - Histologic Subgroup Analysis: It was found that PFS among patients with astrocytoma matched the overall median, while those with oligodendroglioma showed promising results with no median PFS reached, suggesting extended treatment efficacy.
- - Tumor Growth Reversal: Notably, a post-hoc analysis marked a shift from average tumor growth increasing by 16.1% every six months prior to crossover, to a decrease of 2.9% thereafter, highlighting VORANIGO's effectiveness in halting tumor progression.
- - Increased Response Rates: The overall objective response rate rose from 10.7% to 20.8% across the study, with similar improvements seen among both histological groups.
These results were essential in illustrating VORANIGO's potential in enhancing patient outcomes, particularly as the medication accommodates patients who have experienced disease progression.
Safety Profile
Crucially, the safety profile of VORANIGO remained consistent across follow-ups. Adverse events linked to the treatment were largely similar to those reported in earlier studies. Specifically, Grade >3 treatment-emergent adverse events were noted in 31.7% of patients receiving VORANIGO, with no new significant safety concerns emerging from the crossover group.
Common Side Effects Included:
- - Increased liver enzyme levels
- - Fatigue
- - Headaches
Seizure Control & Quality of Life
Further analysis extended beyond survival rates to evaluate how VORANIGO affected seizure control and quality of life. The findings reinforced the medication's role in stabilizing seizure activity, a significant concern for glioma patients. The study noted that the frequency of seizures diminished over time for patients receiving VORANIGO compared to those on a placebo.
Quality of Life Assessments:
At the 2025 data cutoff, the quality of life for patients who experienced seizures was notably preserved. Using the Functional Assessment of Cancer Therapy–Brain (FACT-Br) scale, patients demonstrated a lower risk of deteriorating health outcomes compared to those on placebo, indicating improved life quality attributed to VORANIGO treatment.
Closing Remarks
The INDIGO trial's extended results underline VORANIGO's critical role in the treatment landscape for IDH-mutant glioma, marking a significant advancement in oncology. As the field advances, continuous research is essential to further define the optimal use of such targeted therapies in offering durable relief to patients battling this complex disease. Servier's commitment to innovation and patient care remains a cornerstone of its mission in oncology.
In summary, VORANIGO is positioned as a cornerstone treatment for managing IDH-mutant gliomas, reinforcing positive outcomes and quality of life for patients.